R3 Stem Cell wins trademark for Regenerative Trifecta

By AI, Created 11:29 AM UTC, May 20, 2026, /AGP/ – R3 Stem Cell International has secured U.S. trademark registration for “Regenerative Trifecta,” the brand name for a standardized protocol used across its clinic network in eight countries. The company says the filing formalizes its IP strategy but does not represent FDA review or approval of the underlying therapies.

Why it matters: - The trademark gives R3 Stem Cell International a formal brand identity for a protocol used across about 80 affiliated clinics in eight countries. - The registration may help the company present a more consistent clinical label to patients, clinicians, supply partners, and others across borders. - The trademark does not change the regulatory status of the therapies in the protocol.

What happened: - The U.S. Patent and Trademark Office issued a registration for “Regenerative Trifecta.” - R3 Stem Cell International uses the name for a standardized clinical protocol across its global clinic network. - The network includes roughly 80 affiliated regenerative medicine clinics in eight countries. - The company announced the registration on May 7, 2026.

The details: - The Regenerative Trifecta protocol combines three components: umbilical cord-derived mesenchymal stromal cells, extracellular vesicles often described as exosomes, and platelet-rich plasma. - Each component is administered under the applicable national regulatory framework in the country of treatment. - The company said the trademark establishes brand identity rights for the name only, not approval or endorsement of any medical product or service. - R3 Stem Cell International said its clinics have performed more than 28,000 stem cell procedures globally over the past decade. - The network includes clinics in Mexico, including Tijuana, Puerto Vallarta and Cancun. - The company said the protocol is supported by years of standardization work, supply-chain quality systems and harmonized clinical documentation. - Company President Samantha Brechner said the Regenerative Trifecta brand reflects an internal standard refined for five years. - The company said its clinics in Mexico use COFEPRIS and equivalent authorities in other jurisdictions for oversight of cell-based product rules. - Platelet-rich plasma is prepared autologously from the patient’s own blood at the point of care. - The company said R3 Stem Cell is not a manufacturer or distributor of these components within the United States. - The therapies are offered only at affiliated clinics in jurisdictions where the components are authorized under local rules and under locally licensed clinicians. - The company said it has IRB approval for a global prospective observational registry on safety for regenerative therapies. - The registry is intended to use validated outcome measures, independent oversight, pre-specified analysis and a commitment to publish results regardless of direction. - Additional information is available in the company’s announcement.

Between the lines: - The trademark signals a push to turn an internal treatment standard into a more recognizable commercial and scientific brand. - The move also reflects the challenge of running a cross-border clinic network with different regulatory frameworks, documentation standards and supply rules. - The company’s disclaimer underscores the gap between trademark protection and medical regulatory approval.

What’s next: - R3 Stem Cell International said its research registry will continue under independent oversight. - The company is expected to keep using Regenerative Trifecta as the public label for its standardized protocol across its network. - Future outcomes from the protocol and the registry will depend on local regulatory frameworks and the company’s research program.